ERAS - NASDAQ
Erasca, Inc.
$13.18
+1.2%Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
At a Glance
Live SnapshotErasca, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Erasca, Inc. Cash Flow Statement
ERAS • NASDAQ
| Erasca, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-124.5M | -161.7M | -125M | -242.8M | -122.8M | -101.7M | -12M | |
3.1M | 3.8M | 3.7M | 2.6M | 829K | 540K | 310K | |
0.0 | 0.0 | 0.0 | 0.0 | -1.5M | 0.0 | 0.0 | |
24.9M | 27M | 26.2M | 20.1M | 8.3M | 797K | 122K | |
4.4M | 19.7M | -7M | 101M | 27.8M | 64.3M | -483K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (69K) | (13K) | |
-3.3M | 1.7M | 813K | 15.8M | 7.7M | 3.3M | 1.7M | |
-95.5M | -109.4M | -101.2M | -103.3M | -79.6M | -32.7M | -10.4M | |
INVESTING ACTIVITIES | |||||||
-128K | -60K | -1.8M | -16.6M | -18.9M | -947K | -597K | |
(0.0) | (0.0) | (0.0) | (4M) | (7.7M) | (0.0) | (20.3K) | |
-151M | -403.4M | -314.4M | -134.3M | -105.8M | -99.2M | -58.9M | |
261M | 269.3M | 244.9M | 79.8M | 60.1M | 66.7M | 38.6M | |
-9.5M | -22.5M | -20M | -4M | -7.7M | -37.7M | -20.3K | |
(100.4M) | -156.6M | -91.2M | -71.1M | -64.6M | -71.2M | -20.9M | |
FINANCING ACTIVITIES | |||||||
1.1M | 239.1M | 1.3M | 95.3M | 317M | 0.0 | 0.0 | |
0.0 | 1.6M | 0.0 | 2.8M | 3M | 3M | 0.0 | |
1.1M | 240.7M | 1.3M | 98.1M | 439.4M | 140M | 16.9M | |
CASH FLOW SUMMARY | |||||||
6.1M | -25.3M | -191.1M | -76.3M | 295.2M | 36.1M | -14.4M | |
68.1M | 93.5M | 284.6M | 360.9M | 65.7M | 29.6M | 44M | |
74.2M | 68.1M | 93.5M | 284.6M | 360.9M | 65.7M | 29.6M | |
-95.6M | -132M | -103M | -119.8M | -98.5M | -71.4M | -11M |
SEC Filings
ERAS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 21, 2026 | 2026 |
Related Guides
Continue your ERAS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.